Guidant Corporation (NYSE: GDT) -

Ticker	Firm
GDT	Guidant
JNJ	Johnson & Johnson
BSX	Boston Scientific
ABT	Abbott Laboratories

Boston Scientific has agreed that, if required, it will divest all overlapping assets. 

Boston Scientific has amended its agreement with Abbott under which Boston Scientific has agreed to divest Guidant’s vascular intervention and endovascular businesses, while agreeing to share rights to Guidant’s drug-eluting stent program.  Under the amended agreement with Abbott: the upfront purchase price that Abbott agreed to pay Boston Scientific for the Guidant businesses will increase from $3.8 billion to $4.1 billion; the amount of the loan that Abbott has agreed to make to Boston Scientific will increase from $700 million to $900 million (with a 4 percent interest rate).

INFO SOURCES

Guidant Corporation (NYSE: GDT); Johnson & Johnson (NYSE: JNJ); Boston Scientific Corporation (NYSE: BSX); Abbott Laboratories (NYSE: ABT)